Data is not available at this time.
USANA Health Sciences, Inc. operates in the health and wellness sector, specializing in high-quality nutritional supplements, personal care products, and weight management solutions. The company primarily utilizes a direct-to-consumer, multi-level marketing (MLM) model, leveraging a global network of independent distributors to drive sales. This approach allows USANA to maintain lower fixed costs while benefiting from word-of-mouth marketing and strong customer loyalty. USANA competes in a highly fragmented industry dominated by large players like Herbalife and Nu Skin, but it differentiates itself through science-backed formulations and a focus on premium product quality. The company has a strong presence in North America and Asia-Pacific, with China being a key growth market. USANA’s emphasis on clinical research and product efficacy supports its positioning as a trusted brand in the competitive wellness space. Despite regulatory scrutiny common to MLM models, USANA has maintained compliance and sustained its distributor base, though growth relies heavily on market expansion and product innovation.
In FY 2024, USANA reported revenue of $854.5 million, with net income of $42.0 million, reflecting a net margin of approximately 4.9%. The diluted EPS stood at $2.19, indicating modest profitability. Operating cash flow was $61.0 million, while capital expenditures totaled $10.1 million, suggesting disciplined capital allocation. The company’s efficiency metrics reflect the challenges of its MLM model, including distributor incentives and marketing costs.
USANA’s earnings power is constrained by its reliance on distributor networks, which can lead to variable sales performance. The company generated $61.0 million in operating cash flow, demonstrating its ability to convert revenue into cash. However, capital efficiency is moderate, with limited reinvestment in growth initiatives beyond sustaining operations. The absence of significant debt ($29.0 million) supports financial flexibility.
USANA maintains a solid balance sheet, with $181.8 million in cash and equivalents, providing liquidity for operations and potential strategic moves. Total debt is modest at $29.0 million, resulting in a strong net cash position. The company’s financial health is robust, with no immediate solvency risks, though its reliance on distributor-driven revenue introduces variability.
USANA’s growth has been tempered by market saturation and regulatory hurdles in key regions like China. The company does not pay dividends, opting to retain earnings for reinvestment or share repurchases. Future growth may hinge on product diversification and geographic expansion, particularly in emerging markets where wellness trends are gaining traction.
USANA’s valuation reflects its niche positioning and mixed growth prospects. The market appears cautious, pricing in challenges related to the MLM model and competitive pressures. Investors likely await clearer signs of sustainable revenue growth or margin improvement before assigning a higher multiple to earnings.
USANA’s strengths lie in its science-driven product portfolio and loyal distributor network. However, the outlook remains uncertain due to regulatory risks and reliance on a single sales channel. Success will depend on innovation, market penetration, and adaptability to shifting consumer preferences in the health and wellness sector.
USANA Health Sciences, Inc. 10-K (FY 2024), company filings
show cash flow forecast
Fiscal year | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | |
INCOME STATEMENT | ||||||||||||||||||||||||||
Revenue growth rate, % | NaN | |||||||||||||||||||||||||
Revenue, $ | NaN | |||||||||||||||||||||||||
Variable operating expenses, $m | NaN | |||||||||||||||||||||||||
Fixed operating expenses, $m | NaN | |||||||||||||||||||||||||
Total operating expenses, $m | NaN | |||||||||||||||||||||||||
Operating income, $m | NaN | |||||||||||||||||||||||||
EBITDA, $m | NaN | |||||||||||||||||||||||||
Interest expense (income), $m | NaN | |||||||||||||||||||||||||
Earnings before tax, $m | NaN | |||||||||||||||||||||||||
Tax expense, $m | NaN | |||||||||||||||||||||||||
Net income, $m | NaN | |||||||||||||||||||||||||
BALANCE SHEET | ||||||||||||||||||||||||||
Cash and short-term investments, $m | NaN | |||||||||||||||||||||||||
Total assets, $m | NaN | |||||||||||||||||||||||||
Adjusted assets (=assets-cash), $m | NaN | |||||||||||||||||||||||||
Average production assets, $m | NaN | |||||||||||||||||||||||||
Working capital, $m | NaN | |||||||||||||||||||||||||
Total debt, $m | NaN | |||||||||||||||||||||||||
Total liabilities, $m | NaN | |||||||||||||||||||||||||
Total equity, $m | NaN | |||||||||||||||||||||||||
Debt-to-equity ratio | NaN | |||||||||||||||||||||||||
Adjusted equity ratio | NaN | |||||||||||||||||||||||||
CASH FLOW | ||||||||||||||||||||||||||
Net income, $m | NaN | |||||||||||||||||||||||||
Depreciation, amort., depletion, $m | NaN | |||||||||||||||||||||||||
Funds from operations, $m | NaN | |||||||||||||||||||||||||
Change in working capital, $m | NaN | |||||||||||||||||||||||||
Cash from operations, $m | NaN | |||||||||||||||||||||||||
Maintenance CAPEX, $m | NaN | |||||||||||||||||||||||||
New CAPEX, $m | NaN | |||||||||||||||||||||||||
Total CAPEX, $m | NaN | |||||||||||||||||||||||||
Free cash flow, $m | NaN | |||||||||||||||||||||||||
Issuance/(repurchase) of shares, $m | NaN | |||||||||||||||||||||||||
Retained Cash Flow, $m | NaN | |||||||||||||||||||||||||
Pot'l extraordinary dividend, $m | NaN | |||||||||||||||||||||||||
Cash available for distribution, $m | NaN | |||||||||||||||||||||||||
Discount rate, % | NaN | |||||||||||||||||||||||||
PV of cash for distribution, $m | NaN | |||||||||||||||||||||||||
Current shareholders' claim on cash, % | NaN |